Here we review techniques useful in eliminating or reducing interferences caused by molecules that cross-react in immunoassays. The biochemical rationale for using these techniques is discussed. Examples are taken from recent studies aimed at reducing interferences caused by endogenous molecules such as digoxin-like immunoreactive factors or steroid hormones. In this context the role of protein-binding of cross-reacting molecules is also considered. Immunoassay ligand selectivity can be inherently limited by the heterogeneity of the antigenic response or by the structural similarity of epitopes on multiple ligands. Certain empirical approaches have proved useful in maximizing the analytical specificity of immunoassays. These approaches include isolating the relevant ligands before immunoassay, adjusting the kinetic or equilibrium conditions used during the assays, and developing more specific antisera. The physicochemical properties of the cross-reacting molecule best dictate which technique(s) to use. The approaches discussed here are general and apply to minimizing interference caused by a wide variety of both endogenous and exogenous cross-reacting molecules.
It is well recognized that ligand selectivity in immunoassays is derived from the specificity of the antibodyligand reaction (i.e., high association equilibrium constants derived from high binding energies). In many cases, however, this selectivity toward the principal ligand is inherently limited by the heterogeneous nature of the antigenic response (e.g., polyclonal antisera). However, even when monoclonal antibodies are used, the structural similarity of epitopes on different ligands will create a true site-specific competition between those ligands and the tracer-labeled ligand used in the analysis. That competition is commonly referred to as crossreaction. The issue of cross-reaction in immunoassays is important in several frequently encountered situations: e.g., where endogenous molecules exist that are structurally similar to the principal analyte, where metabolites of the principal analyte are produced in vivo and have common cross-reactive epitopes, and where other Received September 14, 1990 ; accepted December 14, 1990 . structurally similar ligands (e.g., medications) are administered simultaneously.
In these cases the accuracy of the immunoassay results will depend on eliminating or at least minimizing the cross-reactive components in the analysis.
The availability of monoclonal antibodies has greatly increased the specificity (i.e., selectivity) of immunoassays. This is particularly true for analysis of larger molecules such as polypeptides, where two independent epitopes can be bound simultaneously by two antibodies (two-site sandwich assay). This dual-site immunoassay approach substantially increases the probability of dotecting little else but the principal ligand of interest. Some examples of this approach are found in assays of lutropin, follitropin, and choriogonadotropin, where homology between the polypeptide subunits has traditionally made it difficult to achieve immuno-specificity. This dual-epitope approach is commonly used for measuring larger polypeptides (macromolecules). In the case of smaller molecules such as steroids or small peptides (where steric hindrance prohibits the use of two-site assays), we are often faced with finding other solutions to achieve immunoassay specificity.
In situations involving small molecules, certain empirical approaches have proved useful in maximizing the specificity of the assay for the principal ligand. These approaches include isolating the principal ligand from the cross-reactants before immunoassay, adjusting the kinetic conditions of the assay, altering the thermodynamic conditions used in the assay, or developing more-specific antibodies. The efficacy of these techniques depends on the difference in physicochemical properties between the cross-reacting ligand and the principal ligand to be measured. For large molecules or small molecules tightly bound to large proteins, separation by ultrafiltration or chromatography is effective. For molecules similar in size to the principal ligand, separation is much more difficult and techniques such as altering the kinetic or thermodynamic conditions of the immunoassay have proved effective.
Previous reviews (1) (2) (3) (4) and book chapters (5-7) have discussed the theoretical principles needed for understanding the nature of cross-reactivity. However, they provide few examples of practical application of these principles to the reduction of cross-reactivity in immunoassays. In this article we review the more commonly used techniques for reducing assay interferences caused by cross from recent studies on interferences from undefined endogenous digoxin-like immunoreactive factors (DLIF) and from steroid hormones. 4 The concepts and approaches discussed here are general and apply to minimizing interference caused by a wide variety of crossreacting molecules.
Separation of Llgands before Immunoassay
The most obvious approach for eliminating interference from cross-reacting molecules is to remove these molecules from the sample before analysis. One can either remove the cross-reactant or remove the analyte of interest by using a variety of "extraction" steps. The efficiency of the separation will depend on differences in the physicochemical properties of the molecules in question. Molecular size and differential solubility are two important criteria. In both of these cases, binding of these molecules to proteins in the serum sample may play a central role in the efficiency of separation. First we review the role of protein binding in ligand separation and then provide examples of approaches involving ultrafiltration, protein precipitation, and chromatography to remove the cross-reactive ligands before immunoassay.
Role of Protein Binding
if the affinity of one of the two ligands (analyte or cross-reactant) for binding to serum proteins differs sufficiently from that of the other ligand, then separations based on size are useful. One example of this phenomenon is DLIF. DLIF in serum is mostly bound to proteins (8) , whereas digoxin is -23% bound at 37 #{176}C and only 6% bound at 1 #{176}C (9) . Although the protein(s) involved in binding DLIF have not been characterized, diafiltration data from one study suggest some "general" binding characteristics, as depicted in Figure 1 (developed from diafiltration data in ref. 8) . In this hypothesis (representing the normal adult), DLIF exists in different "states": unbound, loosely bound, and tightly bound to serum proteins. The unbound fraction represents <5% of the total DLIF. A "loosely bound" fraction containing another 10% of the total is released from the protein upon heating. The rest of the DLIF (about 85-90%) is tightly bound to protein even after heating. The binding of this last fraction, though very tight, is not covalent because prolonged diafiltration will completely remove DLIF from the protein. The unbound and loosely bound fractions are directly measurable without heating; the tightly bound fraction becomes measurable only after heating (apparently exposing cross-reactive epitopes).
The amount of measurable DLIF (before heating) in normal serum is less than the limit of detection of unmodified digoxin immunoassays, including those involving the most cross-reactive antibodies (10 (10) (11) (12) . The distribution of DLIF binding seems to change in these clinical groups, with most of the increase apparently in the loosely bound fraction. Most of the DLIF in normal serum and the increased amounts in various patient groups is retained during ultrafiltration with a 10 000-Da-cutoff membrane (8) . This indicates that the cross-reactant is associated with high-Me components, e.g., proteins, and suggests that an ultrafiltration step (i.e., separation of high-Mr components from the ligand of interest) may be useful for eliminating DLIF It is important to perform the ultrafiltration step at a low temperature or to include serum-based 
Precipitation of Proteins
When the primary and cross-reactive ligands differ sufficiently in their binding affinities to serum proteins, it may be possible to selectively separate the ligands by precipitating the proteins. Various protein-precipitating reagents-e.g., trichloroacetic acid, sulfosalicylic acid, or ammonium sulfate-may be used. In evaluating the use of precipitating agents, it is important to ensure that the treatment does not dissociate the bound crossreactive ligand to any significant extent.
One example of this dilemma is seen in the proteinprecipitation step used in the Abbott fluorescence polarization immunoassay of digoxin. A report by Soldin et al. (17) compared the use of trichloroacetic acid and sulfosalicylic acid as protein-precipitating pro-treatment steps in an assay relative to detection of DLIF. Serum samples from 37 patients not taking digoxin were measured to have an average DLIF concentration of 0.71 nmolJL digoxin equivalent after precipitation with trichioroacetic acid, compared with 1.61 nmol/L when sulfosalicylic acid was the protein-precipitating reagent. This average increase of 127% in the measured DLIF was likely due to enhanced release of the bound DLIF from the binding proteins by sulfosalicylic acid.
An extension of this problem is the consideration that if separation of proteins before immunoassay is necessary, the process should be as "gentle" as possible so as not to disturb the binding equilibrium between the cross-reactant and the precipitated protein. Disturbing that equilibrium could potentially increase the concentration of the cross-reactive ligand in the protein-free phase. An example of this is discussed by Skogen et al. (18) , who compared the detection of DLIF by several digoxin assays, some of which differed in the protein separation process. The digoxin assay with the leastdisruptive protein separation process showed the least cross-reaction with DLIF and also performed best for measuring digoxin, compared with other assays known not to detect DLIF. Therefore, other factors being equal, a "nondisruptive" protein separation step such as chromatography may be preferable, to avoid increasing the concentration of cross-reactant before immunoassay.
Chromatography

Differences in the chromatographic
properties between principal and cross-reactive ligands often allow their separation. Gault et al. (19) reported an improved digoxin assay in which small reversed-phase columns were used in combination with HPLC, and radioimmunoassay was performed on collected fractions. The initial extraction step made use of C18 "Bond-Elut" columns or "Sep-Pak" columns. After washing the columns, they applied 1 mL of serum, then rinsed the columns with water. Digoxin was eluted with 3 mL of methanol. This extract was further separated by C8 HPLC by using isocratic elution with isopropanol in water (20/80 by vol). Digoxin had a retention time of 34 mm in that system and was well separated from digoxin metabolites (see Figure 2 ) and DLIF (see Figure 3 in ref.
19).
Although this method appears to be specific for digoxin, most of the improved specificity is provided by the time-consuming HPLC step because digoxin metab- of collected fractions. In this method, the improved specificity for digoxin was also primarily obtained in the HPLC step because DLJF and digoxin metabolites remained after the initial extraction steps.
A more time-and cost-effective approach would optimize the extraction steps to remove digoxin metabolites and DLIF, thus eliminating the need for HPLC. One example of this approach is the EMIT C-B digoxin assay (Syva Co., Palo Alto, CA) evaluated by Skogen et al. (18) . They applied 0.5-mL samples to hydrophobic-bonded-phase "Bond-Elut" columns, and washed with 0.1 mollL HC1 and water. Digoxin was eluted with 0.35 mL of methanol in water (60/40 by vol). The EMIT assay was performed on this extract. This "miicolumn" method provided quantitative recovery of digoxin. Serum from pregnant women (Figure 3 ) as well as neonates and patients in renal failure had moderate to marked decreases in DLIF interference with this assay, compared with results of several other methods. The minmcolumn method also shows negligible interference from DLIF in patients with liver disease (21). However, in neither study was removal of digoxin metabolites evaluated.
KInetIc and Thermodynamic ConsIderations For purposes of this discussion, consideration of kinetic and thermodynamic conditions implies the two variables time and temperature of incubation, respectively. Application of the kinetics principle is based on the relationship between the rate constants of association (k0) and dissociation antibody interaction. Assuming that an antibody binds the primary ligand better (i.e., with higher binding energy) than it does a cross-reactant, then K is lower for the cross-reactant; hence, k0, k0ff, or both, for the primary and the cross-reactive ligands must differ. Thus, the relative amounts of primary and cross-reactive ligands that are bound to antibody at any time will vary during the approach to equilibrium. This is equivalent to saying that the apparent cross-reactivity will change until equilibrium is reached and that an appropriately chosen incubation time would minimize crossreactivity.
On the other hand, the hypothesis that altering the thermodynamic conditions will reduce cross-reactivity is based on the temperature dependence of the equilibrium constant (K) and the possibility that this temperature dependence may differ for the primary and crossreactive ligands. Hence, selection of appropriate incubation temperatures may increase the specificity of the immunoassay.
Examples illustrating the use of variations in time and temperature are discussed next.
Increasing Incubation Time
As has been demonstrated, altering the kinetic conditions of an immunoassay affects the specificity of the assay for the primary ligand. A study by Vimng et al. (22) suggests that decreasing the incubation times of steroid assays increases the degree of cross-reaction with structurally similar compounds. Using various antisera to testosterone, androstenedione, and estrone, they measured the cross-reactivity of other steroids as a function of incubation time. Increasing the incubation time gave a progressive decrease in the cross-reactivity ( Figure   4 ). An explanation for this phenomenon is apparent when one compares the half-times for association and dissociation of the primary and cross-reactive ligands with the antibodies. Table 1 shows that the anti-testosterone antiserum had little difference in the association half-times for the various ligands, whereas the dissociation half-times were much less for the crossreactants than for the primary ligand, testosterone. Time required for the "percentage of labeled steroid bound" to achieve a value one half of that reached at equilibrium.
b Time required for the 'percentage of labeled steroid bound" to decrease, in the presence of 10 rig of unlabeled testosterone, to one half of the equilibriumvalue.
A4dione, androst-4-ene-3,17-dione.
Similar results were reported for the other two antisera.
In utilizing these results to reduce cross-reactivity, consider the primary ligand and the cross-reactive hgand that have similar values for k0 but different values for k0ff. Early in the incubation, the binding of crossreactant relative to the binding of the primary ligand is governed predominantly by the similar rates of association, and the apparent cross-reactivity is high. As equilibrium is approached, the dissociation rates contribute substantially to the binding dynamics; therefore, the apparent cross-reactivity decreases. The phenomenon of decreasing the interference from cross-reactivity with DLIF by increasing the incubation time has also been reported for digoxin immunoassays (13, 23, 24) . The study by Graves et al. for minimizing cross-reactivity, but also for determining the time necessary to reach equilibrium. Because crossreactants have their greatest effects early in the binding reaction, the approach to equilibrium, as measured by the amount of tracer that is bound, will be slower in the presence of a cross-reactant.
This phenomenon is illustrated in Figure 6 , where the reaction approaches equilibrium within 2 h in the absence of cross-reactants but considerably later in their presence. If one seeks increased sensitivity by using an immunoassay at equilibrium conditions, it is important to determine the time necessary to reach equilibrium in the presence of the greatest concentrations of cross-reactants likely to be present in samples. Association rate constants have been found to be comparable (10-10 L . mol Os') for a wide variety of antigen-antibody interactions, with differences being even smaller when comparing two antigens binding to the same antibody (25, 26) . Therefore, cross-reactivity must be carefully evaluated before using a shortened incubation time for any immunoassay in which crossreaction is suspected. One obvious example of this problem is in using abbreviated incubation times in digoxin immunoassays to provide "stat" results. As indicated in Figure 5 , the interference due to DLIF increases at shorter incubations.
Increasing Incubation Temperature
The reports cited above show a general decrease of cross-reactivity with increasing incubation time for cross-reactants such as steroids (22) and DLIF (13,23, 24). Those studies also provide a rationale for investigating the effect of incubation temperature on crossreactivity. If the attainment of reaction equilibrium decreases cross-reactivity to the minimum achievable, then the more rapid attainment of equilibrium at higher temperatures would be advantageous in reducing crossreactivity. To better understand this approach, one must consider the relative contributions of enthalpy and entropy changes of the binding reaction and the effects of temperature on the equilibrium constant. In this form the expression emphasizes the dependence of the equilibrium constant on enthalpy and its independence on entropy, relative to changes in temperature (over the narrow range of temperatures used in immunoassays).
If the change in enthalpy of the reaction is near zero, there will be little effect of temperature on the equilibrium constant. If R is negative, increasing the temperature will decrease the equilibrium constant, and vice versa if zH is positive.
The temperature dependence of equilibrium constants for higand binding to antibodies and other proteins was the subject of a report by Keane et al. (27) , who listed the temperature dependence of ligand-binding equilibrium constants for 14 different antibodies and other binding proteins and the calculated enthalpies and entropies of these reactions (see Table 2 ). From the relative contributions of enthalpy and entropy to the free energy of binding (and thus to the equilibrium constant) for these binding reactions, three general groups or "classes" of interactions were described. Group A, comprising small relatively hydrophobic ligands (e.g., steroids) binding to by R near zero and high S. For this group the temperature dependence of the equilibrium constant is small (see Table 2 ). result was perhaps due to additional binding of the steroids to the bovine serum albumin present in their buffer. However, the exact conditions of those experiments were not given and the results are therefore difficult to evaluate.
Thus, a more complex model describing the effect of temperature on DLIF cross-reactivity would have to include its binding to plasma protein(s). As discussed above, about 90% of serum DLIF is tightly bound to serum protein, and no data are available on the thermodynamics or kinetics of that binding or on the nature of the binding protein. However, one might predict that DLIF binding to its serum-binding protein might belong in Group C (Table 2) and be characterized by a large negative enthalpy change. Under these conditions, increasing the incubation temperature would decrease the equilibrium constant for DLIF binding to its serum binding protein so that more unbound DLIF would be present to cross-react with anti-digoxin antibodies. Of course, as discussed above, this prediction is opposite to the experimental data, but is presented as an example of the nuances in evaluating a more complex model. Nonetheless, the apparent failure of this model is informative, in that it suggests that DLIF binding to serum protein(s) may not belong in Group C. The available data may make it difficult to generalize the effect of temperature on cross-reactivity, but these examples indicate the empirical nature of using this approach. Data such as those compiled by Keane et al. (27) are excellent starting points for testing predictions, but need to be extended to include more examples of the various groups and to include consideration of more complex systems with multiple binders.
Use of More-SpecIfic AntibodIes
Another obvious approach to reducing cross-reaction in immunoassays is to develop more-specific antibodies.
Although this approach is more applicable to researchers and reagent manufacturers than to assay users, ample evidence indicates that this approach is worth pursuing.
Selection of Antisera (Polyclonal)
Most studies that include comparative cross-reactivity studies between kits use the manufacturers' recommended assay conditions for each assay studied. Because these conditions (incubation temperature, time, sample volume, etc.) usually vary between assays, it is difficult to determine to what extent differing crossreactivity is due to the specificity of the antisera or to other assay variables. However, the marked differences in cross-reactivity that are sometimes observed strongly suggest that some antisera are significantly more specific for the primary ligand.
In a study by Skogen et al. (18) , several digoxin assays were compared for their detection of DLIF (Figure 3) . The assays from Clinical Assays and Corning were quite similar; both were based on immobilized antibodies (coated tube and coated glass beads, respectively) and neither involved a sample pre-treatment step. The marked difference in the detection of DLIF by these assays strongly suggests that the antiserum in the Corning assay was more specific for digoxin relative to DLIF.
In another study (29), four digoxin assays were evaluated for cross-reactivity with digoxin metabolites. The cross-reactivities of dihydrodigoxin and digitoxin varied considerably from kit to kit. These results suggest that screening of antisera by kit manufacturers early in assay development allows selection of the most specific antisera. This has become common practice by most reputable suppliers of iminunoassay reagents.
Affinity Purification of Antibodies
To the extent that cross-reactivity is attributable to heterogeneous populations of antibodies, each with differing selectivity towards ligands, one may use affinitybinding techniques for purification of more-specific antibodies. Thong et al. (30) used this approach for isolating anti-digoxin antibodies. They coupled digoxin to agarose beads and used a column of this material to immunopurify antibodies from whole antiserum. The immunoreactivity of digoxin metabolites (digoxigenin and its mono-and bisdigitoxides) to the whole antiserum was three-to fourfold higher than that of digoxin itself, however, the use of digoxin-affinity-purified antibodies reduced the immunoreactivity of these crossreactants to that of digoxin.
Selection of Monoclonal Antibodies
The goal of the two approaches discussed above, screening of polyclonal antisera for low cross-reactivity and affinity purification of antisera, is to reduce the population of antibodies to only those that have the desired specificities. The ultimate approach to achieving this goal is the production of a monoclonal antibody. With this technique, the monoclonal antibodies ob- Table 2 ). Cross-reactivity with DHEA (the nonconjugated steroid) varied from 4.3% to 18.5%, and there was extensive variation in cross-reactivity with other steroids.
Ghosh (32) reported similar results for monoclonal antibodies against estriol (Table 3) . Of the two monoclonal antibodies evaluated, 2BD7 had less cross-reactivity with estrone, estradiol, and estetrol than did antibody 1BF7. These results clearly demonstrate the feasibility of screening for monoclonal antibodies with high specificity toward the primary ligand of interest. They also point out two other salient features, i.e., that crossreaction is sometimes inevitable, regardless of the antibody purity, and that assay configuration (RIA vs enzyme immunoassay) predictably has no role in altering the extent of cross-reactivity.
Developing Antisera against Novel Conjugates
Another approach to the production of more-specific antibodies is the use of novel hapten-protein conjugates for immunization.
In an excellent review of steroid immunoassays, Pratt (33) gives a detailed discussion of the effect on antibody specificity of the position of attachment of the hapten to the protein immunogen. The principle here is that the specificity of binding of free hapten to antibodies is determined largely by structural features of the hapten distant from the point of attachment to the protein immunogen. Thong et al. (30) used this approach to produce antibodies against digoxin that would have reduced crossreactivity with digoxin metabolites. Traditionally, antibodies against digoxin have been generated against periodate-oxidized digoxin conjugated to bovine serum albumin or other proteins. By this method the attachment to the protein molecule is at the terminal sugar (see Figure 8) , and antibodies are directed primarily against the lactone ring and steroid "far" end of the (Table 4) . Interestingly, the cross-reactivity of digitoxin, which differs from digoxin only in lacking the hydroxyl group at position 12, was also greatly reduced. Antibodies with similar specificity for the carbohydrate end of digoxin were reported by Shimada et al. (34) , who used bovine serum albumin conjugates attached at the C-17 or C-12 position. However, these antibodies did have marked cross-reactivity with digitoxin. Because of the unique structure of the carbohydrate moiety of digoxin, antibodies directed against that part of the molecule would be unlikely to cross-react with DLIF; however, to our knowledge, this has not been evaluated.
Using Dual-Site Assays
Multi-site immunoassays greatly increase the specificity of immunoassays. In these assays two independent epitopes can be bound simultaneously by two antibodies (two-site sandwich assay). This dual-site immunoassay approach substantially increases the probability of detecting little else but the principal ligand of interest. Some examples of this approach are found in assays for lutropin, follitropin, or choriogonadotropin, where homology between the polypeptide subunits has traditionally made it difficult to achieve immuno-specificity. This approach has also been useful for measuring specific isoenzymes such as creatine kinase MB (35) and prostatic acid phosphatase (36, 37) . Dual-site immunoassays are used for measuring larger polypeptides (macromolecules), but are not useful for smaller molecules such as steroids or small peptides (where steric hindrance is a deterrent to the use of two-site assays).
Effects of Cross-ReactIvity on immunoassay Performance
Improved immunoassay specificity by reduction of cross-reactivity is a valid analytical goal. However, in some situations, this may not be necessary and, in other situations, depending on the method of achieving the improved specificity, other parameters of analytical performance may be compromised.
When is cross-reactivity a problem?
Obviously the cross-reactivity of a particular compound is a problem only if that compound is present in the samples being (39) showed that the apparent cross-reactivity of DLIF may decrease or increase (depending on the assay) in the presence of increasing concentrations of primary ligand ( Figure 9 ). This observation suggests that in some cases cross-reactivity may in practice be less (or greater) than indicated by the cross-reactivity data (usually determined in the absence of the primary ligand).
Does reduction of cross-reactivity improve immunoassay performance? There are two separate aspects to consider: analytical improvements and improvement of clinical utility. With regard to analytical improvement, reduction of cross-reactivity obviously results in an assay that is more specific for the analyte of interest. One method of demonstrating this for digoxin immunoassays was used by Skogen et al. (40) , who found that the digoxin assays least affected by cross-reaction with DLIF showed significantly better correlation with each other than with digoxin assays known to be subject to cross-reaction with DLIF. This implies that the morespecific assays are indeed measuring the same analyte or a more homogeneous analyte. As mentioned above, however, some methods for reduction of cross-reactivity may compromise other aspects of analytical performance. Methods in which a separation step is used to remove cross-reactants, for example, may introduce additional imprecision in the assay or reduce recovery of the analyte of interest.
From a clinical perspective, reduction of cross-reactivity may be undesirable in some cases. Digoxin is but one of many examples where cross-reactivity with other molecules (e.g., metabolites) may be desirable. The poor correlation between the measured concentrations of digoxin in serum and the therapeutic or toxic effects of the drug in patients has been an issue for many years (12). Variability in the metabolism of digoxin (19, 41, 42) and cardioactivity of some digoxin metabolites (43, 44) (and potentially DLIF) may be the cause of the relatively poor correlation between digoxin concentrations and clinical assessment. At this time it has not been established whether highly specific digoxmn immunoassays provide results that are more clinically useful than those of less specific assays.
Methods available for cakulating cross-reactivity in immunoassays.
The approaches we have reviewed are not dependent on the method used for calculating the extent of cross-reactivity. Several different methods are available for calculating cross-reactivity in immunoassays, including calculation of the ratio of the apparent concentration of the analyte of interest to the concentration of the cross-reactant at some arbitrary concentration, the ratio of concentrations of analyte and crossreactant that gives 50% displacement of tracer (45) , or 10% displacement of tracer (2), among others (2,4,46) . Because these methods may give quantitatively different estimates of cross-reactivity, we emphasize that comparisons of cross-reactivity data in the literature must be done with an understanding of the particular method of calculation being used. A review of these calculation methods has been published (47) .
